Evidence map›Paper›PMID 32526187›Full record

ArticleThe Lancet. Respiratory medicine2020

Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

GBD Chronic Respiratory Disease Collaborators

5 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in The Lancet. Respiratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 1,247 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,247citing papers in PubMed, 9 pooled it
138.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04711057 nacompletednot on this mapstarted 2021, after this paper: background citation

CENTR(AR): Lungs Moving

TypeinterventionalSponsorAveiro UniversityRan2021 to 2023Enrolled80ConditionsChronic Respiratory Disease, Lung Diseases, Pulmonary Disease, Chronic Obstructive Pulmonary DiseaseArmsCommunity-based PA program, Pulmonary Rehabilitation
NCT05679609 nacompletednot on this mapstarted 2021, after this paper: background citation

Value of Incentive Spirometry in Routine Management of COPD Patients and Its Effect on Diaphragmatic Function

TypeinterventionalSponsorMenoufia UniversityRan2021 to 2022Enrolled40ConditionsCOPDArmsincentive spirometry
NCT05934617 unknown statusnot on this map

Trajectories of FEV1 After Lung Transplantation: Determinants and Clinical Outcomes

TypeobservationalSponsorParis Translational Research Center for Organ TransplantationRan2020 to 2024Enrolled2,500ConditionsLung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
NCT06528418 recruitingnot on this mapstarted 2024, after this paper: background citation

Exploration and Study on the Identification of Various Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath

TypeobservationalSponsorChromX HealthRan2024 to 2027Enrolled10,000ConditionsLung Cancer, Lung Infection, COPD, BronchitisArmsGas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system
NCT06751537 recruitingnot on this mapstarted 2025, after this paper: background citation

Effectiveness of WearME System for FEV1/FVC, Respiration and Activity Biomarkers in COPD Patients

TypeobservationalSponsorLASARRUS Clinic and Research CenterRan2025 to 2026Enrolled128ConditionsChronic Obstructive Pulmonary Disease (COPD)
3 · Its place in the literature

Who cites it

1,247 citing papers in PubMed, 9 syntheses or guidelines pooled it, 2,174 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Review
  19. Article
  20. Article

1,187 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 4 institutions in 2 countries.

GBD Chronic Respiratory Disease Collaborators
Institute for Health Metrics and Evaluation · USUniversity of Washington · USCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESUniversidad Autónoma de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious attempts to characterise the burden of chronic respiratory diseases have focused only on specific disease conditions, such as chronic obstructive pulmonary disease (COPD) or asthma. In this study, we aimed to characterise the burden of chronic respiratory diseases globally, providing a comprehensive and up-to-date analysis on geographical and time trends from 1990 to 2017.

methodsUsing data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, we estimated the prevalence, morbidity, and mortality attributable to chronic respiratory diseases through an analysis of deaths, disability-adjusted life-years (DALYs), and years of life lost (YLL) by GBD super-region, from 1990 to 2017, stratified by age and sex. Specific diseases analysed included asthma, COPD, interstitial lung disease and pulmonary sarcoidosis, pneumoconiosis, and other chronic respiratory diseases. We also assessed the contribution of risk factors (smoking, second-hand smoke, ambient particulate matter and ozone pollution, household air pollution from solid fuels, and occupational risks) to chronic respiratory disease-attributable DALYs.

findingsIn 2017, 544·9 million people (95% uncertainty interval [UI] 506·9-584·8) worldwide had a chronic respiratory disease, representing an increase of 39·8% compared with 1990. Chronic respiratory disease prevalence showed wide variability across GBD super-regions, with the highest prevalence among both males and females in high-income regions, and the lowest prevalence in sub-Saharan Africa and south Asia. The age-sex-specific prevalence of each chronic respiratory disease in 2017 was also highly variable geographically. Chronic respiratory diseases were the third leading cause of death in 2017 (7·0% [95% UI 6·8-7·2] of all deaths), behind cardiovascular diseases and neoplasms. Deaths due to chronic respiratory diseases numbered 3 914 196 (95% UI 3 790 578-4 044 819) in 2017, an increase of 18·0% since 1990, while total DALYs increased by 13·3%. However, when accounting for ageing and population growth, declines were observed in age-standardised prevalence (14·3% decrease), age-standardised death rates (42·6%), and age-standardised DALY rates (38·2%). In males and females, most chronic respiratory disease-attributable deaths and DALYs were due to COPD. In regional analyses, mortality rates from chronic respiratory diseases were greatest in south Asia and lowest in sub-Saharan Africa, also across both sexes. Notably, although absolute prevalence was lower in south Asia than in most other super-regions, YLLs due to chronic respiratory diseases across the subcontinent were the highest in the world. Death rates due to interstitial lung disease and pulmonary sarcoidosis were greater than those due to pneumoconiosis in all super-regions. Smoking was the leading risk factor for chronic respiratory disease-related disability across all regions for men. Among women, household air pollution from solid fuels was the predominant risk factor for chronic respiratory diseases in south Asia and sub-Saharan Africa, while ambient particulate matter represented the leading risk factor in southeast Asia, east Asia, and Oceania, and in the Middle East and north Africa super-region.

interpretationOur study shows that chronic respiratory diseases remain a leading cause of death and disability worldwide, with growth in absolute numbers but sharp declines in several age-standardised estimators since 1990. Premature mortality from chronic respiratory diseases seems to be highest in regions with less-resourced health systems on a per-capita basis.

fundingBill & Melinda Gates Foundation.

Indexed as

Cost of IllnessAdolescentAdultAgedAged, 80 and overAge FactorsAsthmaChildChild, PreschoolChronic DiseaseFemaleGlobal Burden of DiseaseHumansInfantInfant, NewbornLife Expectancy

Identifiers

PMID32526187
PMCPMC7284317
OpenAlexW3033438356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.